Company news

Ironwood Pharmaceuticals, Inc. news in 2024

Ironwood Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

November 25, 2024

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

November 12, 2024

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

November 6, 2024

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

October 27, 2024

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

October 23, 2024

Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

August 28, 2024

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

August 7, 2024

Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call

July 24, 2024

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

May 20, 2024

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

May 8, 2024

Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference

May 5, 2024

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

April 30, 2024

Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call

April 24, 2024

Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

March 27, 2024

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

February 28, 2024

Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

February 22, 2024

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

February 14, 2024

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call

January 31, 2024

Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance

January 7, 2024

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

January 7, 2024

Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024